Consistent with ivermectin being an allosteric modulator of the ATP/P2X4/P2X7 signaling axis which operates in both cancer and immune cells, differential sensitivity in myeloid cells was P2X7-dependent (Fig. 2C). Here, P2RX7 is linked to cancer.